DiaSorin raises 2024 guidance slightly following Q2 results (updated)

DiaSorin SpA

29/07/2024 16:21

(Adds revenue and adj. core profit in paragraph 3-4, shares
movement in 5)
       July 29 (Reuters) - Italian medical diagnostics group
DiaSorin  DIAS.MI  raised its guidance slightly for 2024 after
reporting on Monday a 9% rise in second-quarter adjusted core
profit.
    The company said it now expects revenue growth this year of
between 6%-7% compared to previous guidance of 5%-7% growth, and
sees its 2024 adjusted core profit margin at about 33% compared
to a previous margin set at 32%-33%.
    Its shares were trading down 2.4% at 101.85 euro by 1440 GMT
but have risen around 10% this year.
    Second quarter adjusted core profit totalled 102 million
euros ($110.23 million), the company said.
        The profit results do not include the company's revenue
from its COVID-related diagnostics, which accounted for around 5
million euros in the second quarter.  
    Revenue net of COVID business rose 7% in the second quarter
at constant exchange rates to 295 million euros mainly thanks to
a good performance by its immunodiagnostic and molecular
diagnostic businesses, it said.
        Its adjusted core profit margin was 34% in the second
quarter 


($1 = 0.9253 euros)

 (Reporting by Alberto Chiumento; Editing by Susan Fenton)
 ((Alberto.chiumento@thomsonreuters.com))